回复：

MONARCH plus 结论

阿贝西利联合NSAI或氟维司群在来自中国、巴西、印度和南非的绝经后晚期乳腺癌女性群体中有显著的、具有临床意义的PFS改善。阿贝西利组的ORR也有显著改善，两个队列中阿贝西利组的肿瘤缩小均大于安慰剂组。¹MONARCH plus的疗效获益与MONARCH 2和MONARCH 3试验一致，而且最常见的不良事件与MONARCH 2和和MONARCH 3 试验是相似的。^2,3AE通常是可监测、可管理和可逆的，并且没有观察到新的安全问题。

参考文献

1. Zhang QY, Sun T, Yin YM, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:1-14. https://doi.org/10.1177/1758835920963925

2. Goetz MP, Toi M, Campone M, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638-3646. https://doi.org/10.1200/jco.2017.75.6155

3. Sledge GW Jr, Toi M, Neven P, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875-2884. https://doi.org/10.1200/JCO.2017.73.7585

词汇表

AE = 不良事件

NSAI = 非甾体类芳香化酶抑制剂

ORR = 客观缓解率

PFS = 无进展生存期